Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
21 Setembro 2023 - 5:05PM
Business Wire
- Three abstracts demonstrate new insights that
can be derived from whole-transcriptome-based thyroid cancer
molecular profiles -
Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters
showcasing new data from the company’s Afirma Genomic Sequencing
Classifier (GSC) will be presented at the 2023 American Thyroid
Association (ATA) Annual Meeting being held in Washington, DC from
September 27 to October 1. Together, these abstracts offer novel
insights into the molecular underpinnings of thyroid nodules and
tumors based on whole-transcriptome RNA sequencing data from
thyroid nodules analyzed with the Afirma GSC.
“As we enter a new era in the personalized diagnosis and
management of thyroid nodules and cancer, it is more important than
ever to advance the science around this cancer so we can ultimately
characterize each patient’s individual molecular profile,” said
Joshua Klopper, MD, Veracyte’s medical director for Endocrinology.
“The abstracts to be presented by our clinical research colleagues
at the ATA meeting show that the Afirma GSC platform can be used to
glean new insights about thyroid nodules and thyroid cancer
preoperatively. We believe that Afirma-based whole-transcriptome
analysis will help drive cancer research and unlock findings that
may ultimately be used in clinical care.”
The following late-breaking posters will be presented at the
2023 ATA Annual Meeting (all times ET):
Title: Leveraging RNA Sequencing for Pre-Operative
Immunophenotyping of BRAFV600E+ Thyroid Nodules Presenter:
Jarod Olay, M.S., UCLA David Geffen School of Medicine
Poster #: 502 Date/Time: September 28; 10:00
a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m. Title:
Molecular Assessment of Isthmus Thyroid Carcinomas
Presenter: Sina Jasim, M.D., Washington University in St.
Louis Poster #: 501 Date/Time: September 28; 10:00
a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m. Title: Sodium
Iodide Symporter (NIS) Expression in Cytologically Indeterminate
and Malignant Thyroid Nodules
Presenter: Prasana Santhanam, M.B.B.S., M.D., The Johns
Hopkins University School of Medicine Poster #: 515
Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35
a.m. – 12:45 p.m.
These abstracts will later be published as an online supplement
to Thyroid, the official journal of the ATA.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that Veracyte can help advance
the science around thyroid cancer so we can ultimately characterize
each patient’s individual molecular profile and that Afirma
analysis can help drive cancer research and unlock findings that
may ultimately be used in clinical care. Additional factors that
may impact these forward-looking statements can be found under the
caption “Risk Factors” in our Annual Report on Form 10-K filed on
March 1, 2023, and our Quarterly Report on Form 10-Q filed for the
three months ended June 30, 2023. Copies of these documents, when
available, may be found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
Veracyte, the Veracyte logo and Afirma are registered trademarks
of Veracyte, Inc. and its subsidiaries in the U.S. and selected
countries.
Veracyte delivers the Afirma Genomic Sequencing Classifier and
TERT DNA analysis from its CLIA laboratory. These tests are not
CE-IVD marked and have not been cleared or approved by the FDA;
their performance characteristics were determined by Veracyte and
they might be considered for Research Use Only in some markets.
Please contact Veracyte for confirmation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921364578/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024